Bandeira Francisco, Griz Luiz, Chaves Narriane, Carvalho Nara Crispim, Borges Lívia Maria, Lazaretti-Castro Marise, Borba Victoria, Castro Luiz Cláudio de, Borges João Lindolfo, Bilezikian John
Arq Bras Endocrinol Metabol. 2013 Aug;57(6):406-24. doi: 10.1590/s0004-27302013000600002.
To conduct a literature review on the diagnosis and management of primary hyperparathyroidism including the classical hipercalcemic form as well as the normocalcemic variant.
This scientific statement was generated by a request from the Brazilian Medical Association (AMB) to the Brazilian Society for Endocrinology as part of its Clinical Practice Guidelines program. Articles were identified by searching in PubMed and Cochrane databases as well as abstracts presented at the Endocrine Society, Brazilian Society for Endocrinology Annual Meetings and the American Society for Bone and Mineral Research Annual Meeting during the last 5 years. Grading quality of evidence and strength of recommendation were adapted from the first report of the Oxford Centre for Evidence-based Medicine. All grades of recommendation, including "D", are based on scientific evidence. The differences between A, B, C and D, are due exclusively to the methods employed in generating evidence.
We present a scientific statement on primary hyperparathyroidism providing the level of evidence and the degree of recommendation regarding causes, clinical presentation as well as surgical and medical treatment.
对原发性甲状旁腺功能亢进症的诊断和管理进行文献综述,包括经典的高钙血症形式以及正常血钙变体。
本科学声明是应巴西医学协会(AMB)的要求,由巴西内分泌学会作为其临床实践指南计划的一部分编写而成。通过检索PubMed和Cochrane数据库以及过去5年在内分泌学会、巴西内分泌学会年会和美国骨与矿物质研究学会年会上发表的摘要来确定文章。证据质量分级和推荐强度改编自牛津循证医学中心的第一份报告。所有推荐等级,包括“D”级,均基于科学证据。A、B、C和D级之间的差异完全是由于生成证据所采用的方法不同。
我们提出了一份关于原发性甲状旁腺功能亢进症的科学声明,提供了关于病因、临床表现以及手术和药物治疗的证据水平和推荐程度。